DIFFERENT EEG ALPHA POWER PROFILES DURING SPACEFLIGHTS MISSIONS – PRELIMINARY RESULTS

Pusil S.¹, Shirah B.H.², Bruña R.¹, Zegarra-Valdivia J.³, Cuesta P.¹, Laohathai C.⁴, Cebolla A. M.⁵, Haueisen J.⁶, Fiedler P.⁶, Cheron G.⁵, Maestú F.¹, Funke M.⁷

¹Center for Cognitive and Computational Neuroscience, Complutense University of Madrid, Spain; ⁴Department of Neurology, Saint Louis University, St. Louis, MO, USA; ⁵Charité – Universitätsmedizin Berlin, Berlin, Germany; ⁶Institute of Biomedical Engineering and Informatics, Technische Universität Ilmenau, Germany; ⁷McGovern Medical School, University of Texas Health Science Center at Houston, Houston, TX, USA



Post-flight (ground level)

INTRODUCTION

Space exploration has long been a frontier that pushes the boundaries of human endurance and adaptability [1]. In this context, spaceflight presents unique challenges to the human neurophysiology, including exposure to microgravity, radiation, isolation, and confinement, which can impact health, performance and mission success [2]. While brief episodes of microgravity have been shown to induce neurophysiological changes, the implications for short-duration and long-duration spaceflights remain uncertain.



MATERIALS & METHODS



Pre-flight (ground level)





This study seeks to explore the extent of **neurophysiological alterations** during space missions, shedding light on potential functional problems and contributing valuable insights to the evolving field neurophysiology. Finally, the study emphasizes the importance of spaceflight 01 electroencephalography (EEG) as a biomarker for predicting changes due to the space environment and objectively assessing the effects of countermeasures, thus enhancing our ability to ensure the well-being and performance of astronauts during space exploration missions.



In-flight (extraterrestrial)

RESULTS









Figure 1. AXIOM-2 EEG recording. (A) Saudis astronaut (S1) during EEG recording, eyes open. (B) EEG setup with conventional wet electrodes.

Figure 2. Comparisons of the DMN alpha power between AXIOM-2 astronaut and the NEUROSPAT experiment (ISS mission for 6 months reported by Cebolla et al., 2016). (A) DMN alpha power decrease trend found for two subjects of the NEUROSPAT (N1 and N5) and in the dataset from the AXIOM-2 (S1). (B) DMN alpha power ratio between flight conditions and the subjects where an alpha power reduction was found in the in-flight condition compared to the pre-flight condition (P < 0.05). (C) No trend found in the DMN alpha power between subjects (N2, N3 and N4) and flight conditions. (D) DMN alpha power between flight conditions and the subjects where no trend was found.



N2 N3 N4

N2 N3 N4



N2 N3 N4

pre-flight

in-flight post-flight

[1] Clément G. R. et al (2020) J Neurophysiol 123, 2037–2063.

[2] Afshinnekoo, E. et al. (2020) Cell 183, 1162–1184.

[3] Cebolla AM. Et al (2016). Sci Rep. 6(1):37824.

[4] Pusil S. et al (2023) Sci Rep Jun 11;13(1):9489.

ACKNOWLEDGEMENT EEG data analysis (QLA, SGM, CP, PS) was in part supported by a grant [NASA Cooperative Agreement NNX16A069A] from Translational Research Institute for Space Health (TRISH) in Houston, TX. The ISS expeditions were funded by the Belgian Federal Science Police Office (CA, CG), and the European Space Agency (ESA) (AO-2004, 118 for CA, CG). Axiom-2 EEG experiment was supported by the Saudi Space Agency and Nebula Research & Development (LLC, Saudi Arabia).

